SCHEMBL2693569

SCHEMBL2693569

CC(C)(C)c1ccc(C(C)(NC(=O)Cn2cnc3ccc(F)c(F)c32)C(=O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.67
CACNA1H O95180 2/20 0.37
CACNA1G O43497 1/20 0.37
CACNA1I Q9P0X4 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PRPS1 P60891 1/20 0.36
NR1I2 O75469 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2C9 P11712 1/20 0.33
IDO1 P14902 1/20 0.33
KCNH2 Q12809 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32
TP53 P04637 1/20 0.32
NR1H4 Q96RI1 2/20 0.32
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9988203 0.84 TRPV1 (0.71) TRPV1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5133535 0.81 TRPV1 (0.79) TRPV1CACNA1HCACNA1GCACNA1ISMN1; SMN2
SCHEMBL30005521 0.80 TRPV1 (1.00) TRPV1ALDH1A1NR1H4
SCHEMBL2692902 0.80 TRPV1 (1.00) TRPV1ALDH1A1NR1H4
SCHEMBL2693400 0.80 TRPV1 (1.00) TRPV1ALDH1A1NR1H4
SCHEMBL9988201 0.78 TRPV1 (0.62) TRPV1CACNA1HCACNA1GCACNA1ISMN1; SMN2
SCHEMBL5133267 0.75 TRPV1 (0.55) TRPV1SMN1; SMN2MEN1KMT2APRPS1
SCHEMBL307885 0.74 TRPV1 (0.53) TRPV1SMN1; SMN2PRPS1ALDH1A1LMNA
SCHEMBL4492187 0.73 TRPV1 (0.83) TRPV1ALDH1A1CYP2C9
SCHEMBL14292204 0.73 TRPV1 (0.85) TRPV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168668-B2 Compounds ASTRAZENECA AB (SE) 2012-05-01 US claimed
US-20100286202-A1 New Compounds ASTRAZENECA AB (SE) 2010-11-11 US claimed
US-20080171770-A1 Compounds ASTRAZENECA AB (SE) 2008-07-17 US claimed
US-8168668-B2 Compounds ASTRAZENECA AB (SE) 2012-05-01 US disclosed
US-20100286202-A1 New Compounds ASTRAZENECA AB (SE) 2010-11-11 US disclosed
US-7618993-B2 Compounds ASTRAZENECA AB (SE) 2009-11-17 US disclosed
US-20080171770-A1 Compounds ASTRAZENECA AB (SE) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286202-A1 New Compounds REN, PCSK9, FURIN TRPV1 117/4885CACNA1H 1969/4885CACNA1G 921/4885
US-20080171770-A1 Compounds REN, PCSK9, SLC10A1 TRPV1 91/4885CACNA1H 1778/4885CACNA1G 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.